Skip to content
- Hyperliquid Strategies Inc. entered a Business Combination Agreement with Sonnet BioTherapeutics Holdings and Rorschach I LLC.
- Chardan Capital Markets may sell up to 160 million shares of Hyperliquid’s common stock under a $1 billion equity facility.
- The share offering depends on the completion of the business combination, which remains uncertain.
Hyperliquid Strategies Inc., a Delaware-based company, has taken a significant step toward expansion through a detailed Business Combination Agreement. The agreement involves Sonnet BioTherapeutics Holdings Inc., Rorschach I LLC, and two merger subsidiaries under Hyperliquid.
The signed transaction is meant to establish a new public body referred to as “Pubco.” The strategy entails two major mergers. First, there is a merge between Rorschach Merger Sub and Rorschach I LLC, which becomes a wholly owned subsidiary of Pubco.
Shortly thereafter, the Company Merger Sub will merge with Sonnet BioTherapeutics, which in turn becomes another direct subsidiary of Pubco. All these moves combine to form a two-structured merger that would enhance the company structure and operations for Hyperliquid’s corporation.
Market Conditions and Underwriting Role of Chardan
This helps the company successfully increase its capital structure. However, the company must complete the transaction before disclosing any public share offerings. Hyperliquid also filed a preliminary prospectus with the United States Securities and Exchange Commission. In respect of the formation of a committed equity facility with Chardan Capital Markets LLC.
As part of the arrangement, Chardan is entitled to offer a maximum of 160 million shares of the common stock of Hyperliquid. The shares, referred to as “Purchase Shares.” It can be offered by virtue of a ChEF Purchase Agreement entered on October 22, 2025.
The facility allows Hyperliquid to raise a maximum aggregate gross proceeds amounting to $1 billion in stock offerings in the future. However, it is dependent on market circumstances, as well as company issuance strategies. It also includes the handling of the resale offers by Chardan as an underwriter.
Potential Growth and Market Expansion for Hyperliquid
The company will also receive different fees, namely the commitment fee and documentation fee, following the effectiveness of the business combination. Despite the fact that Hyperliquid would not sell any shares publicly. It would use the funds from the purchase made by Chardan for its operations.
The entire portfolio is contingent on the success of the business combination with respect to Sonnet BioTherapeutics and Rorschach. If the business combination fails, the company will withdraw its registration statement and issue no shares. These securities remain in the preliminary stage, so investors cannot buy or sell them yet.
There is a wait required for the approval from the SEC in relation to any issuance that is meant to happen. Should it happen, the merge facility for equity could represent a critical period for Hyperliquid Strategies in terms of its period for expansive growth.
Related Reading: Arthur Hayes Predicts Bitcoin to Skyrocket to $1 Million with Japan’s Economic Shift
